Roivant Sciences Stock Price, News & Analysis

Roivant Sciences and Pfizer have launched Priovant Therapeutics to focus on developing innovative therapies for autoimmune diseases. Priovant is advancing brepocitinib, a dual inhibitor of TYK2 and JAK1, showing statistically significant results in five Phase 2 studies. A Phase 3 trial for dermatomyositis (VALOR) has commenced, and top-line results from an ongoing Phase 2b study in systemic lupus erythematosus (SLE) are expected in the second half of 2023. Pfizer retains a 25% equity stake in Priovant and has licensed rights for both brepocitinib and ropsacitinib.

Roivant Sciences (Nasdaq: ROIV) will host a live conference call and webcast on June 28, 2022, at 8:00 a.m. EDT to discuss its financial results for Q4 and the fiscal year ending March 31, 2022. Investors can join the call by dialing +1-844-224-1923 (domestic) or +1-214-989-7105 (international) using conference ID 1036178. A recording of the call will be available on Roivant’s website post-event. The company focuses on improving healthcare delivery and developing transformative medicines.

Dermavant Sciences announced the FDA's approval of VTAMA (tapinarof) cream, a steroid-free topical medication for plaque psoriasis in adults. In the pivotal Phase 3 trials, VTAMA cream showed significant efficacy, with 36%-40% of patients achieving clear skin compared to 6% with a vehicle. The remittive effect lasted approximately four months after treatment cessation. With a favorable safety profile and patient satisfaction rates over 80%, Dermavant aims for a June 2022 product launch. This positions VTAMA as a potential preferred treatment option in a market underserved by recent innovations.

Dermavant Sciences announced the FDA approval of VTAMA cream (tapinarof), a steroid-free treatment for plaque psoriasis in adults. The product showed significant efficacy in Phase 3 trials, with 36%-40% of patients achieving clear or almost clear skin at week 12. The cream provides a median off-treatment remittive effect of approximately four months. Dermavant plans to launch VTAMA in June 2022, with a fully staffed commercial team and manufacturing ready. This approval represents a milestone for Dermavant and offers a new option for patients with high unmet needs in psoriasis treatment.

Roivant Sciences (Nasdaq: ROIV) will participate in four upcoming healthcare investor conferences. CEO Matt Gline will present at the UBS Global Healthcare Conference on May 23, while CFO Richard Pulik will join a fireside chat at the H.C. Wainwright Conference on May 24. Gline will also participate in the Jefferies Healthcare Conference on June 8, followed by Pulik and President Mayukh Sukhatme at the Goldman Sachs Conference on June 14. Live webcasts of these events will be available on Roivant's investor website.

Aruvant Sciences presented clinical data on its gene therapy ARU-1801 for severe sickle cell disease (SCD) at the ASGCT annual meeting on May 16, 2022. The data indicates ARU-1801 significantly reduces vaso-occlusive events and hospitalization days for patients. This therapy uniquely employs reduced intensity conditioning, setting it apart from other treatments. In the ongoing MOMENTUM trial, participants showed durable responses with four out of five experiencing complete resolution of severe events. These findings may enhance patient quality of life and lower healthcare costs.

Roivant Sciences has appointed Dr. Srini Ramanathan as Chief Development Officer, bringing over 20 years of drug development experience from Horizon Therapeutics. Dr. Ramanathan has a proven track record in advancing clinical portfolios and has contributed to multiple drug approvals in virology and oncology. Roivant's subsidiaries, Proteovant Therapeutics and VantAI, have also established collaborations with Blueprint Medicines, Janssen, and Boehringer Ingelheim, focusing on innovative drug development with potential aggregate milestone payments exceeding $1 billion.

Dermavant Sciences announced positive results from the Phase 3 PSOARING 3 long-term extension study for tapinarof cream 1% in treating plaque psoriasis. Over 52 weeks, tapinarof showed durable improvements in efficacy, quality of life, and tolerability without irritation. The study demonstrated significant enhancements in key metrics such as % body surface area (%BSA) affected and Psoriasis Area and Severity Index (PASI). Dermavant aims for FDA approval, with a target action date set for Q2 2022, which could position tapinarof as a novel therapeutic option for psoriasis patients.

Roivant Sciences (Nasdaq: ROIV) announced that CEO Matt Gline will present at Guggenheim’s Targeted Protein Degradation Day on March 16, 2022, at 1:15 p.m. ET. A live webcast will be accessible on the Roivant Investor Relations website. Roivant aims to enhance healthcare delivery by addressing inefficiencies and developing transformative medicines through its innovative Roivant platform. For updates, visit www.roivant.com.